Drugs & Medicine Recalls

Pharmaceutical recall notices, chemical impurities, and biological contamination.

Showing 24 of 400 results
Pharmaceutical
FDA DrugsClass II

Erythromycin Tablets, USP, 250 mg, 30 tablets per bottle, Rx only, Manufactured ...

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

May 27, 2026Zydus Pharmaceuticals (USA) Inc
Pharmaceutical
FDA DrugsClass III

Busulfan Injection, 60 mg per 10 mL (6 mg per mL), 8x10 mL Single-Dose Vials, Rx...

Failed Impurities/Degradation Specifications

May 27, 2026Sagent Pharmaceuticals
Pharmaceutical
FDA DrugsClass II

Atomoxetine Capsules HCL, 10 mg Capsules in unit dose foil strip, strips are pac...

Labeling: Label Mix-Up: Atomoxetine HCl 25mg Capsule incorrectly labeled as Atomoxetine HCl 10mg Capsule.

May 27, 2026Safecor Health, LLC
Pharmaceutical
FDA DrugsClass II

Estradiol Gel, 0.1%, 0.25 mg, 0.25 g per packet, 30 packets per carton, Rx only,...

Defective Container; packets were found to be either empty or partially full.

May 27, 2026ANI Pharmaceuticals, Inc.
Pharmaceutical
FDA DrugsClass I

MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%), NE...

Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus.

May 27, 2026Wisconsin Pharmacal Company
Pharmaceutical
FDA DrugsClass II

Vitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid, Contai...

Presence of a Foreign Substance; black particles observed in liquid

May 27, 2026Safecor Health, LLC
Pharmaceutical
FDA DrugsClass III

Primidone Tablets, USP, 50 mg, 100 Tablets (10 x 10 unit dose blister) per carto...

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

May 27, 2026Amerisource Health Services LLC
Pharmaceutical
FDA DrugsClass II

Gas-X, Simethicone 125 mg/ ANTIGAS, 120 SoftGels, Distributed by: Haleon, Warren...

Labeling: Not Elsewhere Classified- Incomplete inactive ingredient information on the carton labeling.

May 27, 2026Haleon US Holdings LLC
Pharmaceutical
FDA DrugsClass III

Primidone Tablets, USP, 250 mg, 100-count bottle, RX only, Manufactured by: Lann...

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

May 27, 2026Golden State Medical Supply Inc.
Pharmaceutical
FDA DrugsClass II

Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Ph...

Presence of particulate matter: a white thread-like structure in the cartridge

May 27, 2026Lupin Pharmaceuticals Inc.
Pharmaceutical
FDA DrugsClass II

cimzia (certolizumab pegol), 2x200mg/mL PREFILLED SYRINGES (2 single-dose), Rx O...

Lack of Assurance of Sterility

May 27, 2026UCB Biosciences Inc.
Pharmaceutical
FDA DrugsClass II

Erythromycin Tablets, USP, 500 mg, 30 tablets per bottle, Rx only, Manufactured ...

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

May 27, 2026Zydus Pharmaceuticals (USA) Inc
Pharmaceutical
FDA DrugsClass II

Ascend Laboratories, LLC, Metoprolol Succinate Extended-Release Tablets, USP, 25...

Failed Dissolution Specifications

May 20, 2026Ascend Laboratories, LLC
Pharmaceutical
FDA DrugsClass II

Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx o...

Crystallization; identified as Buprenorphine free base

May 20, 2026ENDO USA, Inc.
Pharmaceutical
FDA DrugsClass II

Oasis Tears PF, Preservative-Free Lubricant Eye Drops, 10mL/0.34 Fl OZ Bottle, S...

Lack of Assurance of Sterility: The recall is being initiated out of an abundance of caution following FDA observations noted during a recent inspection of Excelvision.

May 20, 2026Oasis Medical, Inc.
Pharmaceutical
FDA DrugsClass II

Duloxetine Delayed-Release Capsules, 60 mg, Rx Only, 30 capsules, Marketed by: A...

CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.

May 13, 2026Ajanta Pharma Ltd.
Pharmaceutical
FDA DrugsClass II

Duloxetine Delayed-Release Capsules, 20 mg, Rx Only, 60 capsules, Marketed by: A...

CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.

May 13, 2026Ajanta Pharma Ltd.
Pharmaceutical
FDA DrugsClass II

DELFLEX, Dextrose Peritoneal Dialysis Solution with attached stay-safe Exchange ...

Lack of Assurance of Sterility: Potential leaks from perforations in bags.

May 13, 2026Fresenius Medical Care Holdings, Inc.
Pharmaceutical
FDA DrugsClass II

Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 ...

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

May 13, 2026Teva Pharmaceuticals USA, Inc
Pharmaceutical
FDA DrugsClass II

TPN bag (patient specific), Rx# 11-4909703-0-1, Compound Volume 1660 mL per bag,...

Incorrect Product Formulation: product did not contain insulin as listed in the label.

May 13, 2026Central Admixture Pharmacy Services, Inc (CAPS) Los Angeles
Pharmaceutical
FDA DrugsClass II

NAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Di...

Chemical contamination; presence of lead and lithium above specification

May 13, 2026Acella Pharmaceuticals, LLC
Pharmaceutical
FDA DrugsClass II

DELFLEX, Dextrose Peritoneal Dialysis Solution with attached stay-safe Exchange ...

Lack of Assurance of Sterility: Potential leaks from perforations in bags.

May 13, 2026Fresenius Medical Care Holdings, Inc.
Pharmaceutical
FDA DrugsClass II

BD PurPrep, Povidone-iodine 8.3% w/w (0.83% available iodine) with isopropyl alc...

Lack of assurance of Sterility: potential product contamination

May 13, 2026CareFusion 213, LLC
Pharmaceutical
FDA DrugsClass II

Duloxetine Delayed-Release Capsules, 30 mg, Rx Only, a) 90 Capsules, NDC 27241-0...

CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.

May 13, 2026Ajanta Pharma Ltd.